Neurological disorders are among the most pressing healthcare challenges of our time. Alzheimer's, Parkinson's, ALS — these diseases affect hundreds of millions worldwide, and early, accurate diagnosis remains frustratingly elusive for many patients.
That's why the CNS biomarkers market is growing so rapidly. Valued at $6.9 billion in 2024, it's projected to reach $13.8 billion by 2030 — a CAGR of 12.6%.
Three Forces Converging
What's driving this growth? Three powerful forces are converging. First, the sheer scale of the neurological disease burden continues to expand as populations age globally. Second, diagnostic technologies are advancing rapidly — high-resolution mass spectrometry, next-generation sequencing, and single-cell RNA sequencing are enabling detection capabilities that were impossible just a few years ago. Third, the healthcare industry is shifting decisively toward early detection and personalized medicine, and biomarkers are the essential foundation for both.
Why It Matters for Investors and Developers
The implications for investors, diagnostics companies, and pharmaceutical developers are significant. Blood-based biomarker assays, for example, could dramatically expand screening populations by eliminating the need for invasive cerebrospinal fluid collection or expensive PET imaging.
North America currently leads the market with a 35.1% share, but opportunities are emerging across all regions as awareness and diagnostic infrastructure expand.
Download the Report Overview
Curious about the competitive landscape and emerging technologies? Download the free overview of our report Central Nervous System (CNS) Biomarkers: Technologies and Global Markets for the complete market analysis.
→ Download the Free Report Overview